pierre, results would be better, if the drug is finding the right target. That is not the case with Lecanemab. Not just my opinion but the reaction on the market indicates something else.
Molecular iron related mechanisms in AD and drug targets, page-3
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.6¢ | 0.5¢ | $157.8K | 30.91M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 42 | 41052787 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 12963576 | 14 |
View Market Depth
| Last trade - 13.24pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.5¢ |
Change
0.000 ( 16.7 %) |
||||
| Open | High | Low | Volume | ||
| 0.6¢ | 0.6¢ | 0.5¢ | 10005658 | ||
| Last updated 12.46pm 10/05/2024 ? | |||||
| ATH (ASX) Chart |